Validation of the Integrated Model of Health Literacy in Patients With Breast Cancer.

Cancer Nurs

Author Affiliations: Master Program in Long-term Care and School of Gerontology Health Management, College of Nursing, and Cochrane Taiwan, Taipei Medical University; and Department of Physical Medicine and Rehabilitation, Taipei Medical University Hospital, Taiwan (Dr Hou); and School of Occupational Therapy, College of Medicine, National Taiwan University (Ms Huang, Mr Lin, and Dr Hsieh), Taipei, Taiwan; Department of Educational Psychology, University of Wisconsin-Madison (Ms Lee); and Department of Educational Psychology and Counseling, National Tsing Hua University, Hsinchu, Taiwan (Dr Chen); and Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital, Taipei (Dr Hsieh), Taiwan.

Published: August 2019

Background: Health literacy (HL) enables patients with breast cancer to actively participate in health decisions and promote positive health outcomes. The Integrated Model of Health Literacy (IMHL), defined as the personal, situational, and societal/environmental factors that predict the level of HL that can influence health outcomes, incorporates the concepts, determinants, and consequences of HL.

Objective: The aim of this study was to examine the mechanisms and completeness of the IMHL in patients with breast cancer.

Methods: Five hundred eleven Taiwanese patients were prospectively recruited. We conducted structural equation modeling to confirm and modify the predictive pathways linking the HL-related factors in the IMHL.

Results: Results on a total of 511 breast cancer patients showed good model-data fit. An alternative model revealed better fit with 2 pathways added from cancer stage to self-rated health and from cancer duration to shared decision making. Both the original model and alternative model modification revealed that only personal determinants (age, education, cancer stage, and duration) and not situational determinants (marital status) or social/environmental determinants (residence and occupation) could significantly predict the 3 domains of HL. Theorized consequences of HL were significantly influenced by HL in both models.

Conclusions: Our results partially support the relationships proposed in the IMHL for patients with breast cancer as only personal determinants significantly predicted HL.

Implications For Practice: Understanding the predictive pathways of the integrated HL model could help clinicians to tailor HL interventions using a patient's personal determinants to facilitate participation in decision making and promote health for breast cancer patients.

Download full-text PDF

Source
http://dx.doi.org/10.1097/NCC.0000000000000540DOI Listing

Publication Analysis

Top Keywords

breast cancer
20
patients breast
16
integrated model
12
health literacy
12
personal determinants
12
health
8
model health
8
cancer
8
health outcomes
8
imhl patients
8

Similar Publications

Importance: Endocrine treatments, such as Tamoxifen (TAM) and/or Aromatase inhibitors (AI), are the adjuvant therapy of choice for hormone-receptor positive breast cancer. These agents are associated with menopausal symptoms, adversely affecting drug compliance. Topical estrogen (TE) has been proposed for symptom management, given its' local application and presumed reduced bioavailability, however its oncological safety remains uncertain.

View Article and Find Full Text PDF

Detectability of Al18F-NOTA-HER2-BCH PET for Nodal Metastases in Patients With HER2-Positive Breast Cancer.

Clin Nucl Med

January 2025

From the Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine; Peking University Cancer Hospital and Institute, Beijing, China.

Purpose: The aim of this study was to compare Al18F-NOTA-HER2-BCH and 18F-FDG for detecting nodal metastases in patients with HER2-positive breast cancer on PET/CT.

Patients And Methods: In this retrospective study, 62 participants with HER2-positive breast cancer underwent both Al18F-NOTA-HER2-BCH and 18F-FDG PET/CT. Participants were pathologically confirmed as HER2-positive (IHC 3+ or IHC 2+ with gene amplification on FISH).

View Article and Find Full Text PDF

In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician's choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall survival (OS) at the median follow-up of 25.8 months.

View Article and Find Full Text PDF

Purpose: To investigate whether hormone receptor-positive, human epidermal growth factor receptor 2-low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characteristics.

Methods: This study included HR+, HER2-negative early breast cancers from patients enrolled in the phase III, randomized BIG 1-98 and SOFT clinical trials that had undergone tumor genomic sequencing. Tumors were classified HR+HER2-low if they had a centrally reviewed HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization and HR+HER2-zero if they had an HER2 IHC score of 0.

View Article and Find Full Text PDF

Purpose: Financial toxicity (FT) has been linked to higher symptom burden and poorer clinical outcomes for patients with cancer. Despite the availability of validated tools to measure FT, a simple screen remains an unmet need. We evaluated item 12 ("My illness has been a financial hardship to my family and me") of the COmprehensive Score for Financial Toxicity (COST) measure as a single-item FT screening measure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!